Lineage Cell Therapeutics, Inc.
LCTX
$1.23
$0.010.82%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -73.90% | 79.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -73.90% | 79.52% | |||
| Cost of Revenue | -49.01% | 153.48% | |||
| Gross Profit | 53.77% | -518.77% | |||
| SG&A Expenses | 4.78% | 15.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.17% | 76.19% | |||
| Operating Income | -15.96% | -72.95% | |||
| Income Before Tax | -9.14% | 85.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -636.88% | 103.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 43.90% | -41.38% | |||
| Net Income | -665.45% | 102.86% | |||
| EBIT | -15.96% | -72.95% | |||
| EBITDA | -16.39% | -76.33% | |||
| EPS Basic | -644.44% | 102.77% | |||
| Normalized Basic EPS | -5.98% | 85.63% | |||
| EPS Diluted | -933.33% | 102.77% | |||
| Normalized Diluted EPS | 0.85% | 85.63% | |||
| Average Basic Shares Outstanding | 3.31% | 3.63% | |||
| Average Diluted Shares Outstanding | 10.12% | 3.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||